At a glance
ClinicalIndex Comparison RecordN/ACompleted· 55 enrolled
Drug / intervention
Radiotherapy fractionationradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy Fractionation for Patients With HPV+ Oropharyngeal Cancers
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Sep 4, 2018·Updated Feb 20, 2026
In Brief
A clinical study evaluating Radiotherapy fractionation for Oropharyngeal Cancer. Completed, enrolled 55 participants across 1 site.
Detailed Summary
This study is to determine whether a mathematical model can be used to choose a radiation delivery method to improve the rate of a rapid response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOropharyngeal Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartSep 2018
Primary CompletionMar 2022
Study CompletionMar 2024
TodayJul 2026
First PostedSep 4, 2018
Enrollment StartSep 26, 2018
Primary CompletionMar 14, 2022
Study CompletionMar 26, 2024
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.8 years ago
Interventions
Radiotherapy fractionationradiation
Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)